Mount Sinai’s menopause service page is brief. It confirms that clinicians assess and manage menopause concerns, while leaving many medicine details unstated. For a reader researching oral progesterone, that is a meaningful service record, but an incomplete product record.
This September 29, 2026 review separates what Mount Sinai actually describes from questions that require a consultation or an identified capsule label. The reviewed pages do not confirm oral progesterone, Prometrium, a compounded preparation, a dispensing pharmacy or a complete treatment price.
In this article
There is a clinical service behind the overview
Mount Sinai’s menopause page describes a team that manages individual menopause symptoms. It identifies concerns addressed within care, including changes in bleeding and other midlife symptoms. That is direct evidence of a clinical offering. It does not mean that every listed concern calls for the same medicine or that a person can determine suitability from a symptom list.
The Johns Hopkins review examines a more explicit referral and coordination pathway. Comparing how clearly services explain access is useful. Comparing the two as if each sells an identical progesterone capsule would not be supported. Mount Sinai’s short description establishes the service category and leaves the individual clinical assessment ahead.
A list of locations is not a universal medicine offer
The menopause locations page names practices associated with the May Center, Union Square, Queens, Morningside and West. These are New York City access points, not evidence of nationwide remote prescribing. The relevant practice would need to confirm the appointment route and the services available for a particular request.
A large institution can have different professionals and administrative arrangements across locations. The location list does not settle a clinician’s formulary, a pharmacy relationship, insurance acceptance for a specific encounter or prescription availability. Those limits should remain visible when comparing Mount Sinai with a direct online offer. An address answers where care may be organized, not what will be dispensed afterward.
The missing product name matters
No exact oral progesterone product is named in the reviewed Mount Sinai service information. That absence should not be converted into either a promise of availability or a claim that the medicine is never used. It means the public service description cannot answer the product question.
The oral progesterone purpose guide begins with why a medicine is being considered. The Prometrium review works at a different level, examining an identified oral product. Keeping these levels separate prevents a familiar brand from being silently inserted into a clinic review. A future prescription would need its own name, route, intended role and professional explanation before its label could be meaningfully assessed.
Ingredient questions need the whole label
Prometrium provides a concrete example of why formulation identity matters. The current label lists peanut oil and includes a peanut-allergy contraindication. That is not a finding about a medicine supplied by Mount Sinai; the institution’s reviewed pages have not identified one. Nor does it establish that every capsule with progesterone as its active ingredient contains the same ingredients.
The excipient guide explains the distinction without choosing a product for the reader. A clinician can evaluate the relevant medical history, and a pharmacist can clarify the ingredients of an actual dispensed product. The general service page cannot verify a capsule’s compatibility with an individual allergy or justify changing its formulation.
Research activity does not identify a prescription
Mount Sinai’s menopause overview also discusses research. Institutional participation in research is a different kind of statement from a current product label or a comparison of treatment outcomes. The program page does not establish that a particular study tested the capsule a patient might receive, or that research participation guarantees a superior personal result.
The Northwestern Medicine review makes another evidence distinction because its program expressly mentions off-label treatment. In each case, the useful question is what the statement actually describes. A research program, an approved product and a clinician’s proposed use are not interchangeable evidence. This review does not derive a prescribing recommendation from Mount Sinai’s institutional research description.
Safety remains specific even when the website is brief
A lack of detailed medicine information on a service page does not reduce the importance of a later product’s warnings. Prometrium’s label includes contraindications and addresses dizziness and drowsiness. Its patient information supplies product-specific cautions; it is not evidence that a Mount Sinai patient has experienced those effects or that every menopause treatment shares an identical label.
The drowsiness questions guide distinguishes an unwanted effect from the purpose of treatment. A professional discussion must connect the chosen medicine to the person’s circumstances. This review cannot establish that connection from a location list, and it offers no capsule schedule, self-adjustment advice or substitute for assessment of a new concern.
What would make an appointment estimate useful
The reviewed service and location pages do not give a complete consultation-and-prescription price. An estimate would need to identify the practice, the encounter and what is included. A future medicine’s cost is a separate unresolved item until the product and coverage are known. There is no published capsule subscription to compare here.
Our follow-up guide adds the question of responsibility after the visit: who explains a prescription, receives concerns and handles later requests. Mount Sinai is supported as a real menopause-care service. The fair conclusion remains limited to that documented role, with oral formulation, prescribing outcome, costs and the individual follow-up arrangement still to be clarified.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Mount Sinai — Menopause Care and TreatmentsOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29
- Mount Sinai — Menopause Treatment LocationsOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29
- DailyMed — Prometrium progesterone capsule, Acertis Pharmaceuticals LLCCurrent exact oral Prometrium DailyMed label, updated July 23, 2026; patient leaflet revision February 2026. Does not establish provider supply. · Checked 2026-09-29